公开(公告)号：US20240350617A1

公开(公告)日：2024-10-24

申请号：US18762296

申请日：2024-07-02

Applicant: ModernaTX, Inc.

Inventor： Giuseppe CIARAMELLA ,  Sunny HIMANSU

IPC: A61K39/155 ,  A61K39/00 ,  A61K39/12 ,  A61K39/215 ,  A61P11/00 ,  C07K16/10

CPC classification number: A61K39/155 ,  A61K39/12 ,  A61K39/215 ,  A61P11/00 ,  C07K16/10 ,  C07K16/1027 ,  A61K2039/53 ,  A61K2039/55511 ,  A61K2039/55555 ,  A61K2039/6018 ,  A61K2039/70 ,  C07K2317/76 ,  C12N2760/18034 ,  C12N2760/18334 ,  C12N2760/18434 ,  C12N2760/18534 ,  C12N2760/18634 ,  C12N2770/20034 ,  Y02A50/30

Abstract: The disclosure relates to ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.

公开(公告)号：US12121577B1

公开(公告)日：2024-10-22

申请号：US18606473

申请日：2024-03-15

Applicant: Nutcracker Therapeutics, Inc.

Inventor： Samuel Deutsch ,  Daniel Frimannsson ,  Nicole Fay ,  Colin McKinlay ,  Ole Haabeth

IPC: A61K39/12 ,  A61K39/00 ,  A61P35/00

CPC classification number: A61K39/12 ,  A61P35/00 ,  A61K2039/53 ,  A61K2039/54 ,  A61K2039/55522 ,  A61K2039/55538 ,  A61K2039/892

Abstract: Provided herein are examples of mRNA treatment nanoparticles and methods of using them to treat a patient. An mRNA treatment nanoparticle may include one or more mRNAs encoding a tumor-specific antigen and an immunomodulatory agent; and a delivery vehicle molecule encapsulating the one or more mRNAs.

公开(公告)号：US20240342265A1

公开(公告)日：2024-10-17

申请号：US18626704

申请日：2024-04-04

Applicant: SICHUAN ANCOCARE BIOPHARMACEUTICAL, Ltd.

Inventor： Li YU

IPC: A61K39/12 ,  A61K35/768 ,  A61K39/00 ,  A61P37/04 ,  C07K14/705 ,  C12N7/00

CPC classification number: A61K39/12 ,  A61K35/768 ,  A61P37/04 ,  C07K14/70532 ,  C12N7/00 ,  A61K2039/5254 ,  A61K2039/585 ,  C12N2770/24122 ,  C12N2770/24132 ,  C12N2770/24134 ,  C12N2770/24162 ,  C12N2770/24171

Abstract: The invention provides a recombinant West Nile virus, in which the amino acid sequence of envelope E protein is genetically modified to attenuation, and its RNA genome is inserted with a foreign gene fragment. The engineered E gene contains the mutation of five amino acids for reducing its neural virulence to the central nervous system; the integrated foreign gene between E and S1 gene makes a new chimerical virus. Thus, the present invention provides the application of this attenuated West Nile virus as a vaccine in preventive medicine and the application of the RNA-viral vector as a novel gene-drug in the pharmaceutical industry. The newly attenuated virus may fill the gap of no live-attenuated vaccine to the West Nile virus epidemic. The attenuated and recombinant virus can be used as an RNA oncolytic virus to target solid tumors, especially neural tumors, for cancer therapy with higher safety.

公开(公告)号：US12116401B2

公开(公告)日：2024-10-15

申请号：US17585981

申请日：2022-01-27

Applicant: Bill & Melinda Gates Medicl Research Institute

Inventor： Laura M. Walker

IPC: C07K16/10 ,  A61K9/00 ,  A61K39/12 ,  A61P31/16 ,  C12N15/85 ,  A61K45/06

CPC classification number: C07K16/1027 ,  A61K9/0019 ,  A61K39/12 ,  A61P31/16 ,  C12N15/85 ,  A61K45/06 ,  C12N2760/18534

Abstract: Anti-RSV antibodies with neutralizing potency against RSV subtype A and RSV subtype B are provided, as well as methods for their identification, isolation, generation, and methods for their preparation and use are provided.

公开(公告)号：US12115218B2

公开(公告)日：2024-10-15

申请号：US17312441

申请日：2019-04-17

Applicant: LUOYANG SEIWEI BIOTECHNOLOGIES CO., LTD.

Inventor： Kegong Tian ,  Yongmei Liu ,  Xuke Zhang

IPC: A61K39/39 ,  A61K39/02 ,  A61K39/12 ,  A61K39/187 ,  A61K39/245 ,  A61P31/04 ,  A61P31/20 ,  A61K39/00

CPC classification number: A61K39/39 ,  A61K39/0241 ,  A61K39/12 ,  A61K39/187 ,  A61K39/245 ,  A61P31/04 ,  A61P31/20 ,  A61K2039/5252 ,  A61K2039/55511 ,  A61K2039/55577

Abstract: The present disclosure provides an adjuvant composition containing 0.2%-15% w/v carbomer, 0.1%-0.5% w/v lecithin, and 0.03%-0.2% w/v ginsenoside. The adjuvant composition of the present disclosure cannot only ensure the long-term clarification and/or stability of the vaccine, but also can effectively stimulate the inactivated antigens and subunit antigens therein to produce high-titer antibodies for immune protection. The inactivated vaccines or subunit vaccines prepared by the adjuvant composition of the present disclosure can be used as a diluent for freeze-dried live virus antigens and has no toxic effect on the live virus antigens.

公开(公告)号：US20240335526A1

公开(公告)日：2024-10-10

申请号：US18528323

申请日：2023-12-04

Applicant: ModernaTX, Inc.

Inventor： Giuseppe Ciaramella ,  Sunny Himansu

IPC: A61K39/155 ,  A61K39/00 ,  A61K39/12 ,  A61K39/215 ,  A61P11/00 ,  C07K16/10

CPC classification number: A61K39/155 ,  A61K39/12 ,  A61K39/215 ,  A61P11/00 ,  C07K16/10 ,  C07K16/1027 ,  A61K2039/53 ,  A61K2039/55511 ,  A61K2039/55555 ,  A61K2039/6018 ,  A61K2039/70 ,  C07K2317/76 ,  C12N2760/18034 ,  C12N2760/18334 ,  C12N2760/18434 ,  C12N2760/18534 ,  C12N2760/18634 ,  C12N2770/20034 ,  Y02A50/30

Abstract: The disclosure relates to respiratory virus ribonucleic acid (RNA) vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.

公开(公告)号：US20240335523A1

公开(公告)日：2024-10-10

申请号：US18294912

申请日：2022-08-04

Applicant: The Regents of the University of California

Inventor： Rebecca Dubois ,  John Dzimianski

IPC: A61K39/145 ,  A61K39/12 ,  A61K39/21 ,  A61K39/215 ,  C07K14/005

CPC classification number: A61K39/145 ,  A61K39/12 ,  A61K39/21 ,  A61K39/215 ,  C07K14/005 ,  C07K2319/20 ,  C07K2319/91 ,  C12N2760/16122 ,  C12N2760/16134

Abstract: Provided are polypeptides comprising, consisting essentially of, or consisting of a foldon domain comprising an N-linked glycosylation motif. In some embodiments, the foldon domain is fused to a heterologous amino acid sequence, non-limiting examples of which include immunogenic polypeptides. Trimers of three polypeptides of the present disclosure are also provided, as are related immunogenic compositions and methods of inducing an immune response in an individual. Also included are vectors, e.g., cloning and/or expression vectors that include a nucleic acid sequence encoding a foldon as disclosed herein.

公开(公告)号：US12109260B2

公开(公告)日：2024-10-08

申请号：US18336439

申请日：2023-06-16

Applicant: TAKEDA VACCINES, INC.

Inventor： Jill A Livengood ,  Hansi Dean ,  Htay Htay Han ,  Raman Rao ,  Jackie Marks ,  Gary Dubin ,  Laurence De Moerlooze ,  Hetal Patel ,  Sushma Kommareddy

IPC: A61K39/00 ,  A61K9/00 ,  A61K39/12 ,  A61K39/39 ,  A61P31/14 ,  C12N7/00

CPC classification number: A61K39/12 ,  A61K9/0019 ,  A61K39/39 ,  A61P31/14 ,  C12N7/00 ,  A61K2039/5252 ,  A61K2039/54 ,  A61K2039/545 ,  A61K2039/55505 ,  C12N2770/24034 ,  C12N2770/24071 ,  C12N2770/24134 ,  C12N2770/24151 ,  C12N2770/24163 ,  C12N2770/24164

Abstract: The present disclosure relates to Zika virus vaccines and immunogenic compositions having one or more antigens from a Zika virus (e.g., a Zika virus clonal isolate, a non-human cell adapted Zika virus, etc.), and methods of treatments and uses thereof.

公开(公告)号：US12109257B2

公开(公告)日：2024-10-08

申请号：US18045812

申请日：2022-10-11

Applicant: Gritstone bio, Inc.

Inventor： Wade Blair ,  Karin Jooss ,  Amy Rachel Rappaport ,  Ciaran Daniel Scallan ,  Leonid Gitlin

IPC: A61K39/12 ,  A61K39/00 ,  A61P31/12 ,  C07K14/47 ,  C07K14/74 ,  C12N15/86

CPC classification number: A61K39/001191 ,  A61K39/001188 ,  A61K39/12 ,  A61P31/12 ,  C07K14/4748 ,  C07K14/70539 ,  C12N15/86 ,  A61K2039/53 ,  A61K2039/545 ,  A61K2039/585 ,  A61K2039/6037 ,  A61K2039/605 ,  A61K2039/70

Abstract: Disclosed herein are alphavirus vectors that include neoantigen-encoding nucleic acid sequences derived from a tumor of a subject. Also disclosed are nucleotides, cells, and methods associated with the vectors including their use as vaccines.

公开(公告)号：US12102674B2

公开(公告)日：2024-10-01

申请号：US18477695

申请日：2023-09-29

Applicant: Cambridge Technologies LLC

Inventor： Ben Hause

IPC: A61K39/12 ,  A61P31/16 ,  A61K39/00

CPC classification number: A61K39/12 ,  A61P31/16 ,  A61K2039/5156 ,  A61K2039/552 ,  A61K2039/58 ,  C12N2710/14034 ,  C12N2710/14042

Abstract: Immunogenic compositions for inducing a universal immune response to influenza, and particularly influenza A, by eliciting anti-neuraminidase antibodies which provide protection against heterologous influenza infection. Compositions comprising recombinant expression vectors expressing neuraminidase in cultured cells dispersed in a pharmaceutically-acceptable carrier comprising cell culture media, and optional adjuvant. Methods of inducing immune responses against influenza, and particularly influenza A, by eliciting anti-neuraminidase antibodies in a host animal susceptible to infection.